Imeik Technology Development Co.,Ltd.
300896
Hisse Senetlerindeki Sıralama
#3838
Imeik Technology Development Co.,Ltd. specializes in the research, development,... Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
Hisse Fiyatı
$14.33
Piyasa Değeri
$4.34B
Değişim (1 gün)
3.76%
Değişim (1 yıl)
-38.92%
Ülke
CN
Ticaret Imeik Technology Development Co.,Ltd. (300896)
Kategori
Healthcare
Imeik Technology Development Co.,Ltd. (300896) için EPS
June 2026 itibariyle EPS TTM: $0.53
Imeik Technology Development Co.,Ltd. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $0.53'dir. 2023 yılı sonunda, şirketin EPS'si $0.87 idi; bu, 2022 yılındaki EPS olan $0.60 ile önceki yıla göre artış.
Imeik Technology Development Co.,Ltd. için 2014 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $0.53 | -40.73% |
| 2024 | $0.89 | 2.66% |
| 2023 | $0.87 | 43.49% |
| 2022 | $0.60 | 21.58% |
| 2021 | $0.50 | 60.03% |
| 2020 | $0.31 | 60.24% |
| 2019 | $0.19 | 75.48% |
| 2018 | $0.11 | 40.94% |
| 2017 | $0.08 | 60.00% |
| 2016 | $0.05 | 189.94% |
| 2015 | $0.02 | -41.92% |
| 2014 | $0.03 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| $8.85 | 1,577.73% |
US
|
|
| $6.41 | 1,114.26% |
FR
|
|
| - | - |
JP
|
|
| $3.32 | 529.38% |
US
|
|
| - | - |
CH
|
